1. Introduction

An autonomous healthcare ecosystem is an integrated digital or technological healthcare environment in which multiple functions—such as diagnosis, patient monitoring, electronic health records, telemedicine, pharmacy services, insurance, medical devices, AI decision-support, laboratory services and payment—operate through interconnected platforms.

Examples include an ecosystem combining:

• AI diagnostic software;
• wearable or implantable medical devices;
• electronic health records (EHRs);
• telehealth platforms;
• digital pharmacies;
• health-insurance interfaces;
• clinical decision-support systems;
• cloud infrastructure;
• patient-data platforms; and
• autonomous or semi-autonomous medical systems.

Competition-law problems arise when the operator of such an ecosystem acquires control over several complementary markets and uses that control to restrict competitors.

The central concern is not simply that one firm is technologically successful. The concern is whether ecosystem integration creates durable market power that can be leveraged from one healthcare market into another.

2. Meaning of an Autonomous Healthcare Ecosystem

An autonomous healthcare ecosystem can be represented as:

Patient → Wearable/Device → Data Platform → AI System → EHR → Doctor/Hospital → Pharmacy/Laboratory → Insurer → Payment

A single company may control several layers.

For example:

A company supplies the wearable device, owns the health-data platform, operates the AI diagnostic system, provides cloud infrastructure, and controls the API through which hospitals obtain patient information.

This creates several potential competition concerns.

Major characteristics

1. Multi-sided markets
2. Network effects
3. Large healthcare datasets
4. High switching costs
5. Interoperability dependence
6. Platform lock-in
7. Vertical integration
8. AI-driven decision systems
9. Data advantages
10. Potential self-preferencing

3. Competition-Law Framework

The principal legal questions normally concern:

A. Market definition

Relevant markets may include:

• EHR software;
• electronic prescribing;
• digital diagnostic services;
• AI diagnostic systems;
• wearable health monitoring;
• health-data interoperability;
• telehealth;
• digital pharmacy;
• clinical decision-support software;
• hospital information systems.

The ecosystem may therefore consist of several adjacent but legally distinct markets.

4. Dominance and Market Power

An ecosystem operator may possess market power because of:

• installed user base;
• proprietary datasets;
• network effects;
• interoperability advantages;
• exclusive contracts;
• high switching costs;
• technological standards;
• control over APIs;
• control over authentication;
• integration with hospitals and insurers.

Market share remains relevant, but in digital healthcare market share alone may not capture ecosystem power.

5. Major Competition Concerns

A. Self-Preferencing

An ecosystem operator may rank its own:

• diagnostic service;
• pharmacy;
• insurance product;
• wearable;
• AI model; or
• telehealth service

above competing services.

For example, an AI-health platform could recommend its own diagnostic laboratory while technically allowing rival laboratories to participate.

The competition question becomes whether the platform's control over an important gateway is being used to disadvantage rivals.

6. Tying and Bundling

A dominant healthcare platform might require:

EHR software + proprietary AI diagnostic tool

or:

wearable device + proprietary cloud subscription

or:

hospital-management system + proprietary pharmacy service.

Tying becomes particularly important where competitors could otherwise compete in the secondary market.

7. Interoperability Restrictions

Interoperability is one of the most important competition issues.

An ecosystem operator may restrict:

• API access;
• data portability;
• device compatibility;
• EHR interoperability;
• clinical-data exchange;
• third-party AI access;
• integration with competing devices.

The effect may be to make switching technically difficult even when competing products are available.

8. Data Advantage and Data Foreclosure

Healthcare ecosystems can accumulate enormous quantities of:

• patient records;
• diagnostic information;
• biometric data;
• treatment histories;
• medication information;
• insurance information;
• device-generated data.

A dominant firm might restrict rivals from accessing necessary data while using the same data internally.

This creates a potential data foreclosure problem.

Competition authorities may therefore examine whether:

data that is commercially indispensable is being withheld from competitors without legitimate justification.

9. Network Effects

Healthcare ecosystems can exhibit strong two-sided or multi-sided network effects.

For example:

More doctors → more patients → more health data → better AI → more doctors

This can create a self-reinforcing competitive advantage.

Once a platform reaches sufficient scale, competitors may face a chicken-and-egg problem:

• doctors do not join because there are few patients;
• patients do not join because there are few doctors.

This issue was particularly important in the Surescripts litigation.

10. Switching Costs and Lock-In

Patients and hospitals may be reluctant to change platforms because migration involves:

• transferring medical records;
• retraining staff;
• changing workflows;
• replacing hardware;
• reconfiguring APIs;
• validating AI systems;
• regulatory compliance;
• cybersecurity testing.

Consequently, even a technically superior competitor may struggle to enter.

11. Exclusive Dealing

Healthcare ecosystems may use:

• hospital exclusivity;
• insurer exclusivity;
• pharmacy exclusivity;
• physician contracts;
• device exclusivity;
• preferred-provider agreements.

The competition concern becomes stronger where a dominant ecosystem prevents rivals from obtaining sufficient scale.

12. Leveraging

An ecosystem owner may use dominance in one market to expand into another.

For example:

Dominant EHR → preferential access to AI diagnostics → AI market expansion

or:

Dominant wearable → exclusive access to health data → insurance-market advantage

or:

Dominant digital pharmacy → preferential placement within healthcare platform

This is often described as ecosystem leveraging.

13. Autonomous AI and Algorithmic Competition

Autonomous healthcare ecosystems create a newer competition issue.

An AI system may autonomously:

• select suppliers;
• recommend healthcare providers;
• determine product rankings;
• allocate appointments;
• negotiate procurement;
• select pharmacies;
• determine reimbursement pathways.

If the algorithm systematically favors affiliated companies, competition authorities may examine the design and effects of the algorithm, rather than merely the wording of contracts.

14. Six Important Case Laws / Enforcement Decisions

1. FTC v. Surescripts, LLC

United States — Electronic prescribing

This is one of the most directly relevant cases to autonomous healthcare ecosystems.

Surescripts operated electronic-prescribing networks connecting healthcare providers, EHR systems, pharmacies and other participants.

The FTC alleged that Surescripts maintained monopolies in electronic-prescription routing and eligibility through exclusionary practices, including loyalty and exclusivity arrangements.

The case was especially significant because of network effects.

Surescripts benefited from having large numbers of participants on both sides of the platform:

more pharmacies → greater value to EHRs → more EHRs → greater value to pharmacies.

The FTC alleged that contractual arrangements made it difficult for participants to use competing platforms.

The district court subsequently granted the FTC partial summary judgment concerning market definition and monopoly power. The parties later settled, with restrictions imposed on specified exclusionary conduct.

Relevance

The case demonstrates that:

• healthcare platforms can be two-sided markets;
• network effects can strengthen monopoly power;
• loyalty arrangements can create de facto exclusivity;
• interoperability and multihoming are important competitive factors.

Application: An autonomous healthcare ecosystem connecting hospitals, physicians, pharmacies and AI providers could create similar network-based foreclosure risks.

2. European Commission — Google Android

European Union — tying and ecosystem leverage

The Google Android decision concerned Google's integration of different products and services within the Android ecosystem.

The European Commission found competition concerns concerning, among other conduct, tying Google Search and Chrome with other components of the Android ecosystem.

The Commission considered whether Google's control over the Android app-store ecosystem gave its related services competitive advantages that rivals could not effectively replicate.

Relevance to healthcare

The same analytical framework can apply where a healthcare ecosystem controls a critical platform.

For example:

Dominant EHR platform + mandatory proprietary AI diagnostic service

could potentially raise analogous tying and leveraging questions.

The important competition-law concepts include:

• distinct products;
• dominance in the tying product;
• coercive linkage;
• foreclosure;
• barriers to entry;
• objective justification.

3. United States v. Microsoft Corp.

United States — software ecosystem and tying

The Microsoft litigation remains important for understanding competition in integrated technological ecosystems.

The case concerned Microsoft's position in operating systems and its conduct toward competing technologies, including browser-related integration.

The broader principle is relevant to healthcare ecosystems because technological integration can have competitive consequences when a dominant platform controls an important gateway.

Healthcare application

Consider:

Dominant hospital operating platform → proprietary AI diagnostic tool → restricted access for rival AI providers

Competition authorities could ask whether integration is a legitimate technological improvement or whether the platform is using its dominance to foreclose competing products.

The case is therefore particularly relevant to:

• tying;
• leveraging;
• interoperability;
• exclusionary conduct;
• platform power.

4. FTC v. Illumina, Inc. / Illumina–GRAIL

United States — genomics ecosystem

The Illumina/GRAIL dispute is particularly relevant to healthcare ecosystems because it involved a company operating upstream in genomic sequencing and a company developing cancer-detection technology.

The competition concern involved the relationship between:

genomic sequencing technology → downstream cancer-detection testing

The FTC challenged the acquisition on the basis that Illumina's position in sequencing could affect competition in the emerging downstream cancer-testing market.

The case illustrates the importance of vertical integration and ecosystem expansion in healthcare technology.

Relevance

An ecosystem owner does not necessarily have to eliminate an existing competitor to create a competition problem.

A concern may arise where control over an important upstream input gives the integrated company the ability or incentive to disadvantage downstream rivals.

Potential healthcare examples include:

• sequencing platforms and diagnostic AI;
• medical-device platforms and software;
• EHRs and clinical AI;
• imaging systems and diagnostic algorithms.

5. Illumina/GRAIL — European Commission Merger Proceedings

European Union — vertical/ecosystem foreclosure

The European proceedings concerning Illumina and GRAIL provide another important illustration of competition analysis in healthcare technology.

The European Commission examined whether Illumina's position in next-generation sequencing could be used to restrict competition in the emerging market for cancer-detection tests.

The case is important because healthcare technology markets increasingly contain interdependent layers rather than isolated products.

Competition lesson

Authorities may examine:

1. upstream market power;
2. downstream competitive conditions;
3. access to essential technologies;
4. incentives to foreclose competitors;
5. innovation effects;
6. effects on emerging markets.

This is directly relevant to autonomous healthcare ecosystems where one company controls both the technological infrastructure and healthcare application layer.

6. Qualcomm — Commission Decision / Qualcomm Litigation

EU — technology ecosystem and exclusionary payments

The Qualcomm proceedings provide a broader technology-platform example involving payments and incentives connected with chipset supply.

The case concerned the use of financial incentives in a technologically interdependent market and the potential exclusion of competing suppliers.

Healthcare relevance

Similar arrangements could theoretically arise where a healthcare ecosystem gives:

• hospitals discounts for using only its devices;
• insurers incentives to use its platform;
• physicians financial incentives to use its AI system;
• pharmacies rebates for routing transactions through its ecosystem.

The legal issue would depend on the applicable dominance, foreclosure and effects analysis.

The important principle is that commercial incentives can have exclusionary effects when used by a dominant ecosystem operator.

15. Additional Important Competition Authorities' Approach: Google–Android Interoperability

The modern regulatory approach is increasingly moving beyond traditional tying cases toward interoperability obligations.

In July 2026, the European Commission adopted measures under the Digital Markets Act requiring Google to provide effective interoperability for competing AI services with specified Android features. The Commission stated that competing AI services should receive access to Android capabilities comparable to those available to Google's own services.

Although this is not a healthcare case, it is highly relevant to autonomous healthcare ecosystems.

For example:

If a dominant health-device operating system gives its own medical AI access to data or device functionality that rival AI providers cannot obtain, interoperability may become a competition issue.

16. Comparative Case-Law Table

17. Essential-Facility-Type Issues

A healthcare ecosystem may control infrastructure that rivals cannot realistically duplicate.

Examples include:

• unique medical datasets;
• hospital interoperability infrastructure;
• proprietary device protocols;
• critical APIs;
• electronic-prescribing networks;
• diagnostic databases.

The competition-law question may become whether refusal of access is capable of excluding competitors and whether access can reasonably be provided.

However, not every valuable database or platform constitutes an essential facility. Authorities generally examine the specific legal test applicable to the jurisdiction.

18. Interoperability as a Competition Remedy

Possible remedies include:

1. API access

Allowing competitors controlled access to technical interfaces.

2. Data portability

Allowing patients and healthcare providers to transfer data.

3. Non-discrimination

Preventing a platform from giving affiliated healthcare services preferential access.

4. Multihoming

Allowing hospitals, doctors and pharmacies to use competing platforms simultaneously.

5. Data-access remedies

Providing competitors access to specified data under appropriate privacy and security safeguards.

6. Structural separation

In exceptional circumstances, separating infrastructure from downstream healthcare services.

19. Privacy and Competition Must Be Distinguished

Healthcare competition law cannot ignore privacy.

Patient data may be highly sensitive.

Therefore, a competition remedy requiring data sharing must consider:

• patient consent;
• data minimisation;
• cybersecurity;
• anonymisation/pseudonymisation;
• purpose limitation;
• confidentiality;
• healthcare regulations.

Thus:

Competition law does not automatically require unrestricted access to patient data.

The objective is to prevent competitively unjustified foreclosure while maintaining legitimate privacy and security protections.

20. Autonomous Healthcare Ecosystem: Hypothetical Example

Assume HealthAI Corp. operates:

1. a wearable glucose monitor;
2. an EHR;
3. an AI diagnostic platform;
4. a cloud system;
5. a digital pharmacy;
6. an insurer interface.

HealthAI then introduces the following rules:

Third-party diagnostic AI cannot access wearable data.

Hospitals receive discounts if they use HealthAI's AI exclusively.

HealthAI's AI receives real-time data while rival AI systems receive delayed data.

HealthAI's pharmacy appears first in patient recommendations.

Patients cannot export complete medical histories.

This creates several potential competition-law issues.

Possible theories

Refusal/interoperability issue

→ rivals cannot access necessary interfaces.

Self-preferencing

→ affiliated pharmacy receives preferential treatment.

Exclusive dealing

→ hospitals are discouraged from using competing AI.

Tying

→ EHR users are required to purchase HealthAI's AI.

Data foreclosure

→ rivals cannot obtain equivalent data.

Leveraging

→ EHR dominance is extended into AI diagnostics.

Switching-cost foreclosure

→ patients cannot easily migrate records.

21. Effects on Competition

Authorities would potentially examine whether conduct results in:

Reduced entry

New healthcare AI companies cannot obtain sufficient data or users.

Reduced innovation

Competitors cannot develop alternative diagnostic systems.

Higher prices

Hospitals and insurers become dependent on one ecosystem.

Reduced choice

Patients receive fewer healthcare technology alternatives.

Reduced quality

The dominant ecosystem has weaker competitive pressure.

Reduced interoperability

Users become technically locked into the ecosystem.

22. Efficiency Defences

Integration is not automatically anticompetitive.

Healthcare companies may have legitimate reasons for ecosystem integration.

For example:

• cybersecurity;
• patient safety;
• clinical accuracy;
• fraud prevention;
• quality control;
• regulatory compliance;
• reduction of medical errors;
• faster diagnosis;
• better interoperability.

A company may therefore argue:

Restricting third-party access is necessary to protect patient safety.

Competition authorities would need to distinguish legitimate technical or healthcare justifications from restrictions that unnecessarily exclude rivals.

23. Special Importance of Patient Safety

Autonomous healthcare systems are different from ordinary digital platforms because errors can cause physical harm.

Therefore, competition analysis may need to consider:

Competition ↔ Innovation ↔ Safety ↔ Privacy

For example, unrestricted third-party access to a medical device could create cybersecurity risks.

Consequently, a proportionate solution might be:

certified third-party access subject to technical and clinical safety standards

rather than unrestricted access.

24. India-Relevant Competition Analysis

Under India's Competition Act, 2002, autonomous healthcare ecosystems could potentially raise issues under:

Section 3

Anti-competitive agreements, including:

• exclusive arrangements;
• tying;
• refusal-related arrangements;
• vertical restrictions.

Section 4

Abuse of dominant position, including conduct involving:

• unfair or discriminatory conditions;
• denial of market access;
• limiting technical or scientific development;
• leveraging dominance in one relevant market into another.

Sections 5 and 6

Combinations become relevant where healthcare technology companies acquire:

• AI companies;
• medical-device platforms;
• digital pharmacies;
• health-data companies;
• diagnostic technology companies.

The Competition Commission of India may therefore need to consider not merely traditional healthcare market shares but also:

• data advantages;
• network effects;
• switching costs;
• interoperability;
• ecosystem integration;
• innovation competition.

25. Key Doctrinal Issues

The most important competition-law questions for autonomous healthcare ecosystems are:

1. Ecosystem dominance

Can dominance in one healthcare technology market confer power over another?

2. Data advantage

When does control over healthcare data become a competitive barrier?

3. Interoperability

Can a dominant platform restrict API or technical access?

4. Self-preferencing

Can an ecosystem favour its own healthcare services?

5. Tying

Can access to one healthcare service be conditioned upon purchasing another?

6. Exclusive dealing

Can hospitals or doctors be prevented from using competing systems?

7. AI discrimination

Can algorithms systematically disadvantage competing providers?

8. Mergers

Can an incumbent acquire emerging technologies that may become future competitors?

9. Innovation foreclosure

Can ecosystem control prevent technological alternatives from developing?

10. Patient choice

Can ecosystem lock-in ultimately reduce meaningful choice for patients?

26. Conclusion

Autonomous healthcare ecosystems represent a convergence of healthcare, AI, data, devices, software and digital platforms. Their competition-law significance lies in the possibility that control over one layer can be leveraged into several adjacent healthcare markets.

The most important competition concerns are:

ecosystem dominance + network effects + data advantages + interoperability restrictions + self-preferencing + tying + exclusivity + switching costs + vertical foreclosure.

The Surescripts litigation is particularly instructive because it demonstrates how network effects and contractual restrictions can reinforce power in a healthcare platform. The Google Android, Microsoft, Illumina/GRAIL, and Qualcomm matters provide complementary principles concerning platform leverage, tying, vertical integration and exclusionary incentives.

For future autonomous healthcare systems, competition authorities are likely to examine not merely market share, but also control over data, interfaces, standards, algorithms, users and complementary healthcare services.